Monte Rosa Therapeutics (GLUE) Common Equity (2020 - 2026)

Monte Rosa Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $521.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 89.68% year-over-year to $521.9 million in Q1 2026; TTM through Mar 2026 was $521.9 million, a 89.68% increase from a year earlier, with the FY2025 full-year figure at $233.1 million, up 4.54% from the prior year.
• Common Equity improved to $521.9 million in Q1 2026 per GLUE's latest filing, from $233.1 million in the prior quarter.
• Across five years, Common Equity topped out at $521.9 million in Q1 2026 and bottomed at $152.5 million in Q1 2024.
• The 5-year median for Common Equity is $243.7 million (2023), against an average of $256.5 million.
• Across the five-year window, Common Equity jumped 637.61% in 2022 and slumped 37.42% in 2024, its largest moves.
• Year by year, Common Equity stood at $271.4 million in 2022, then plunged by 33.96% to $179.2 million in 2023, then gained by 24.37% to $222.9 million in 2024, then increased by 4.54% to $233.1 million in 2025, then surged by 123.94% to $521.9 million in 2026.
• Per Business Quant, the three latest GLUE Common Equity figures stand at $521.9 million (Q1 2026), $233.1 million (Q4 2025), and $245.8 million (Q3 2025).